We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Neurogenetics, a clinical-stage biopharmaceutical company focused on discovering
and developing breakthrough small molecule drugs to treat diseases and disorders
of the central nervous system, has changed its name to TorreyPines Therapeutics.
Cancer vaccine developer Epimmune Inc. said it agreed to merge with IDM SA,
a privately held French biopharmaceutical company, in an all-stock transaction.
Under terms of the agreement, IDM shareholders will receive about 3.77 shares
of Epimmune common stock for each IDM share held.
Metabasis Therapeutics has said two clinical trials of its experimental diabetes
treatment were halted after two patients who were also taking the widely used
diabetes drug metformin suffered serious health problems.
Innovive Pharmaceuticals, a biopharmaceutical company headquartered in Manhattan,
announced it has licensed worldwide rights for the use of Opioid Growth Factor
(OGF) in oncology from Penn State.
Abbott India Ltd has informed BSE that the company entered into a fresh distribution
agreement with Novo Nordisk India Pvt Ltd for sale and distribution of their
insulin products in India for the period Jan. 1, 2005, to Dec. 31, 2006.
Cancer drug developer ImmunoGen has said that French
drug company sanofi-aventis Group initiated clinical testing with huMy9-6-DM4
-- the anti-CD33 Tumor-Activated Prodrug compound that it licensed from ImmunoGen
-- triggering a $2 million milestone payment to the company.
The best way for drug and device manufacturers to receive the fastest possible
coverage decisions from the Centers for Medicare & Medicaid Services (CMS)
is to submit all relevant information on their products during the initial request
for a Medicare national coverage determination (NCD), the agency states in a
new draft guidance.
The FDA has issued a warning letter to dietary supplement maker ABCO Laboratories,
accusing the company of promotional activities that violate the Federal Food,
Drug, and Cosmetic Act.